Hultcrantz, Rolf

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 2,287

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,965

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,067

Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 717

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 394

Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives

Elmberg, M., Hultcrantz, R., Ekbom, A., Brandt, L., Olsson, S., Olsson, R., Lindgren, S., Lööf, L., Stål, P., Wallerstedt, S., et al. (2003) · Gastroenterology

Iron Metabolism and DisordersGenetic factors in colorectal cancer

Cited by 273

Increased Risk of Primary Sclerosing Cholangitis and Ulcerative Colitis in First-Degree Relatives of Patients With Primary Sclerosing Cholangitis

Bergquist, A., Montgomery, S. M., Bahmanyar, S., Olsson, R., Danielsson, Å., Lindgren, S., Prytz, H., Hultcrantz, R., Lööf, L., Sandberg–Gertzén, H., et al. (2008) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 188

Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease

Hagström, H., Nasr, P., Ekstedt, M., Stål, P., Hultcrantz, R., & Kechagias, S. (2019) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 132

Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease

Reilly, N. R., Lebwohl, B., Hultcrantz, R., Green, P. H. R., & Ludvigsson, J. F. (2015) · Journal of Hepatology

Celiac Disease Research and ManagementLiver Disease Diagnosis and Treatment

Cited by 110

A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis

Hultcrantz, R., Olsson, R., Danielsson, Å., Järnerot, G., Lööf, L., Ryden, B. O., Wahren, B., & Broomé, U. (1999) · Journal of Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 107

Pregnancy in patients with primary sclerosing cholangitis

Janczewska, I., Olsson, R., Hultcrantz, R., & Broome, U. (1996) · Liver

Liver Diseases and ImmunityPregnancy and Medication Impact

Cited by 63

Regulatory effects of tumor necrosis factor-alpha and interleukin-6 on HAMP expression in iron loaded rat hepatocytes

Dzikaite, V., Holmström, P., Stål, P., Eckes, K., Hagen, K., Eggertsen, G., Gåfvels, M., Melefors, Ö., & Hultcrantz, R. (2006) · Journal of Hepatology

Iron Metabolism and DisordersTrace Elements in Health

Cited by 26